Form 4: Director Amy Dodrill Acquires PROCEPT BioRobotics Stock

Director Amy Dodrill of PROCEPT BioRobotics Corp. reported the acquisition of restricted stock units and stock options on June 9, 2026.

Summary

• Amy M. Dodrill, a Director at PROCEPT BioRobotics Corp. (PRCT), has reported transactions involving securities.
• On June 9, 2026, Dodrill acquired 3,315 shares of Common Stock via Restricted Stock Units (RSUs).
• Additionally, on the same date, Dodrill was granted a stock option to purchase 5,853 shares of Common Stock at an exercise price of $28.78.
• The RSUs vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting, subject to continued service.
• The stock option also vests in full on the earlier of the one-year anniversary of the grant date or the next annual meeting, subject to continued service, and expires on June 8, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents standard insider compensation and equity grants rather than a significant strategic shift or financial performance indicator.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• Granting of stock options and RSUs to a director aligns their interests with shareholders.
• The transaction indicates continued engagement and commitment from a key leadership member.

Risks

• Vesting of RSUs and stock options is contingent upon continued service, implying a risk of forfeiture if service is terminated before vesting.
• The stock option has an exercise price of $28.78, meaning the stock price needs to exceed this level for the option to be profitable.

Future Outlook

The vesting conditions for both the RSUs and stock options are tied to continued service and specific future dates, indicating a forward-looking incentive structure for the director.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are common in the biotechnology and medical device sectors as companies use equity-based compensation to attract and retain talent and align executive interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of stock by a director can be viewed positively, suggesting confidence in the company's future. However, the transaction is primarily an equity grant and not an open market purchase.
• Employees: The structure of the RSUs and stock options reflects standard compensation practices within the industry, potentially influencing employee morale and retention.
• Management: The grant of equity aligns management's incentives with shareholder value creation.

Next Steps

• Continued service by Amy Dodrill through the vesting dates for the RSUs and stock options.
• Monitoring of PROCEPT BioRobotics Corp.'s stock performance relative to the stock option exercise price.

Key Dates

Keywords

PROCEPT BioRobotics Corp, PRCT, Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock Units, Amy Dodrill, Director, Securities Acquisition